PDCD1 and non-small cell lung carcinoma: Like the recent study from Ohue and colleagues (15) that reported a strong correlation between serum antibodies (NY-ESO-1 and XAGE1) and clinical response to anti–PD-1 monotherapy for NSCLC, we have demonstrated the predictive value of 5-TAAbs panel for responses to both ICIs monotherapy and ICIs-based combination therapy for NSCLC in our study.